Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; BEBYP Study Investigators.

Ann Oncol. 2015 Apr;26(4):724-30. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

PMID:
25600568
2.

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.

Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Barbara C, Fontanini G, Crinò L, Blandino G.

Clin Colorectal Cancer. 2014 Mar;13(1):37-45.e4. doi: 10.1016/j.clcc.2013.11.006. Epub 2013 Nov 14.

PMID:
24503111
3.

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.

Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8.

PMID:
21903485
4.

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A.

J Natl Cancer Inst. 2011 Jan 5;103(1):21-30. doi: 10.1093/jnci/djq456. Epub 2010 Dec 1.

PMID:
21123833
5.

Consequences of targeted treatments for second-line therapy.

De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F.

Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Review.

PMID:
20943621
6.

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.

Lancet Oncol. 2010 Sep;11(9):845-52. doi: 10.1016/S1470-2045(10)70175-3. Epub 2010 Aug 9.

PMID:
20702138
7.

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.

Crit Rev Oncol Hematol. 2011 Jun;78(3):243-51. doi: 10.1016/j.critrevonc.2010.06.003. Epub 2010 Jul 8.

PMID:
20619672
8.

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Masi G, Fornaro L, Cupini S, Loupakis F, Vasile E, Baldi GG, Stasi I, Salvatore L, Falcone A.

Nat Rev Clin Oncol. 2009 Nov;6(11):670-4. doi: 10.1038/nrclinonc.2009.148.

PMID:
19861994
9.

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A.

Br J Cancer. 2009 Jun 2;100(11):1720-4. doi: 10.1038/sj.bjc.6605075. Epub 2009 May 12.

10.

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.

Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A.

Ann Surg. 2009 Mar;249(3):420-5. doi: 10.1097/SLA.0b013e31819a0486.

PMID:
19247029
11.

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A.

Ann Oncol. 2006 Aug;17(8):1249-54. Epub 2006 Jun 9.

PMID:
16766580
12.

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A.

Cancer Chemother Pharmacol. 2006 Nov;58(5):585-93. Epub 2006 May 6.

PMID:
16680463
13.

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.

Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A.

Ann Surg Oncol. 2006 Jan;13(1):58-65. Epub 2006 Jan 1.

PMID:
16372158
14.

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A.

Ann Oncol. 2004 Dec;15(12):1766-72.

PMID:
15550581
15.

A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C, Cupini S, Del Tacca M.

Clin Cancer Res. 2004 Mar 1;10(5):1657-63.

16.

5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.

Allegrini G, Falcone A, Di Marsico R, Lencioni M, Masi G, Galli C, Cupini S, Pfanner E, Marcucci L, Conte PF.

Am J Clin Oncol. 2004 Feb;27(1):101-5.

PMID:
14758142
17.

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P.

J Clin Oncol. 2002 Oct 1;20(19):4006-14.

PMID:
12351598
18.

[Continuous versus intermittent infusion in chemotherapy of colorectal cancer].

Falcone A, Masi G, Allegrini G, Cupini S.

Tumori. 2001 Jan-Feb;87(1 Suppl 1):S45-6. Italian. No abstract available.

PMID:
11300022

Supplemental Content

Loading ...
Support Center